ライフサイエンスコーパス: uterine bleeding

1 e evaluation and treatment of mild-to-severe uterine bleeding.

2 , to either abate or mitigate the effects of uterine bleeding.

3 ve endometrial sampling only in the event of uterine bleeding.

4 or the effects on recurrent VTE and abnormal uterine bleeding.

5 tion with placenta previa but not with other uterine bleeding.

6 rhea, while 24.1% in the COCP group reported uterine bleeding.

7 ce of uterine cancers in women with abnormal uterine bleeding.

8 venous malformation (AVM) is a rare cause of uterine bleeding.

9 d women with symptomatic fibroids, excessive uterine bleeding (a score of >100 on the pictorial blood

10 edical conditions from endometrial cancer to uterine bleeding and as an important component of oral c

11 Among women with abnormal uterine bleeding and dissatisfaction with medroxyprogest

12 es of reproductive age experiencing abnormal uterine bleeding and postpartum hemorrhage.

13 ce-monthly leuprolide acetate in controlling uterine bleeding and were significantly less likely to c

14 e delayed puberty, early menopause, abnormal uterine bleeding, and overlapping SCD-related and menstr

15 women aged 45 years and older with abnormal uterine bleeding attending a tertiary gynaecological dia

16 women globally will be affected by abnormal uterine bleeding (AUB) at some point in their reproducti

17 urveillance of adverse events, with abnormal uterine bleeding (AUB) emerging as a reported concern in

18 ent understanding and management of abnormal uterine bleeding (AUB) in adolescents.

19 have suggested an increased risk of abnormal uterine bleeding (AUB) in women of reproductive age trea

20 ined (i) whether COVID is linked to abnormal uterine bleeding (AUB), (ii) if long COVID symptoms vary

21 Dysfunctional uterine bleeding (DUB) is a common presenting problem fo

22 e polycystic ovary syndrome (PCOS), abnormal uterine bleeding, endometriosis, infertility, and pregna

23 d in this group vs 34.5% in the non-abnormal uterine bleeding group).

24 n the standard-of-care group (major abnormal uterine bleeding) had a bleeding event.

25 The term dysfunctional uterine bleeding has been replaced by AUB.

26 Abnormal uterine bleeding is the leading indication for discontin

27 Abnormal uterine bleeding occurred more frequently with rivaroxab

28 smoking was not found to be associated with uterine bleeding of unknown etiology (relative risk = 1.

29 or placental abruption, placenta previa, and uterine bleeding of unknown etiology in pregnancy.

30 1,000 pregnancies, while placenta previa and uterine bleeding of unknown etiology were indicated in 3

31 or placental abruption, placenta previa, and uterine bleeding of unknown origin suggests that these t

32 The adjusted HR for all abnormal uterine bleeding (on vs off hormonal therapy) was 1.02 (

33 us gynecological symptoms including abnormal uterine bleeding, pain, and infertility, but there is li

34 oprimary efficacy end points were control of uterine bleeding (PBAC score of <75) and reduction of fi

35 ) are associated with irregular or excessive uterine bleeding, pelvic pain or pressure, or infertilit

36 leiomyomas are a frequent cause of abnormal uterine bleeding, pelvic pain, and infertility.

37 cy termination (indicated by weight loss and uterine bleeding) reversed the process in 81% of rats in

38 tumors of the myometrium and cause irregular uterine bleeding, severe anemia, and recurrent pregnancy

39 oms were postmenstrual spotting, pain during uterine bleeding, technical issues with catheter inserti

40 sts are needed to triage women with abnormal uterine bleeding to a reference histology test.

41 ents with symptomatic fibroids and excessive uterine bleeding to receive 3 months of daily therapy wi

42 One patient had grade 3 uterine bleeding (treatment unrelated).

43 Triage of women with abnormal uterine bleeding using the WID-qEC test could reduce the

44 roscopy was estimated in women with abnormal uterine bleeding, using histopathologic findings as a re

45 Uterine bleeding was controlled in 90% of patients recei

46 At 13 weeks, uterine bleeding was controlled in 91% of the women rece

47 Abnormal uterine bleeding was noted in 52 participants (24.6%) an

48 it frequently causes episodes of unscheduled uterine bleeding, which could be associated with prolife

49 the incidences of recurrent VTE and abnormal uterine bleeding with and without concomitant hormonal t

50 The observed increased risk of abnormal uterine bleeding with rivaroxaban needs further explorat